TRIM25 promotes Capicua degradation independently of ERK in the absence of ATXN1L

Derek Wong 1,2, Lisa Sogerer 3, Samantha S. Lee 4, Victor Wong 5, Amy Lum 2, Adrian B. Levine 1, Marco A. Marra 6 and Stephen Yip 1,2,7*

Abstract

Background: Aberrations in Capicua (CIC) have recently been implicated as a negative prognostic factor in a multitude of cancer types through the derepression of targets downstream of the mitogen-activated protein kinase (MAPK) signaling cascade, such as oncogenic E26 transformation-specific (ETS) transcription factors. The Ataxin-family protein ATXN1L has previously been reported to interact with CIC in both developmental and disease contexts to facilitate the repression of CIC target genes and promote the post-translational stability of CIC. However, little is known about the mechanisms at the base of ATXN1L-mediated CIC post-translational stability.

Results: Functional in vitro studies utilizing ATXN1L KO human cell lines revealed that loss of ATXN1L leads to the accumulation of polyubiquitinated CIC protein, promoting its degradation through the proteasome. Although transcriptomic signatures of ATXN1L KO cell lines indicated upregulation of the mitogen-activated protein kinase pathway, ERK activity was found to contribute to CIC function but not stability. Degradation of CIC protein following loss of ATXN1L was instead observed to be mediated by the E3 ubiquitin ligase TRIM25 which was further validated using glioma-derived cell lines and the TCGA breast carcinoma and liver hepatocellular carcinoma cohorts.

Conclusions: The post-translational regulation of CIC through ATXN1L and TRIM25 independent of ERK activity suggests that the regulation of CIC stability and function is more intricate than previously appreciated and involves several independent pathways. As CIC status has become a prognostic factor in several cancer types, further knowledge into the mechanisms which govern CIC stability and function may prove useful for future therapeutic approaches.

Keywords: Capicua, CIC, ATXN1L, MAPK, Ubiquitin, Proteasomal degradation, TRIM25, Glioblastoma, Breast carcinoma

Background

Capicua (CIC), a member of the high-mobility group (HMG) box protein superfamily, is a highly conserved nuclear sensor of receptor tyrosine kinase (RTK) activation. CIC was first identified in Drosophila melanogaster as a regulator of growth and proliferation of specific tissues during development and exists as two isoforms (CIC-S and CIC-L) [1–6]. In general, CIC acts as a repressor of receptor tyrosine kinase (RTK)-responsive genes and is inactivated through phosphorylation by ERK, a member of the mitogen-activated protein kinase (MAPK) cascade [2, 5–8]. The most well-characterized mammalian targets of CIC are the oncogenic E26 transformation-specific (ETS) transcription factor family genes ETV1/4/5 which promote cell proliferation, motility, and invasion, downstream of RTK.

Mutations in CIC were first identified in type I low-grade glioma (LGG) (50–70%), a subtype of LGG defined...
by simultaneous IDH mutation and 1p19q codeletion [9–11]. More recently, dysregulation of CIC activity has been associated with negative prognostic features and/or oncogenesis in several human cancer types [12] including sarcoma [13], glioblastoma [14], hepatocellular carcinoma [15] lung adenocarcinoma [16], and pancreatic adenocarcinoma [17]. This may be due to the subsequent upregulation of RTK-responsive genes such as the oncogenic ETS transcription factors (ETV1/4/5) [15–23]. In addition to the loss of function mutations, post-translational dysregulation of CIC has also been reported in multiple contexts. In glioblastoma, CIC inactivation occurs as a result of ERK phosphorylation and subsequent degradation through interaction with the E3-ligase PJA1 [14] or promotes nuclear export by the kinase c-Src [24]. Conversely, dysregulation of CIC through loss of ATXN1L has been observed in several other cancer subtypes including low-grade glioma and prostate, stomach, pancreatic, gastric, and lung adenocarcinomas [17, 25].

ATXN1L is a member of the Ataxin protein family which has been shown to be a potent regulator of CIC function in both development and cancer [17, 25, 26]. Previous studies investigating murine development have indicated some level of functional redundancy between ATXN1L and its homolog ATXN1. However, these studies have also highlighted that loss of ATXN1L affected CIC function much more profoundly and robustly compared to the loss of ATXN1, which is also consistent in cancer [26, 27]. Although several studies have consistently reported that the loss of ATXN1L results in the post-translational dysregulation of CIC stability and function, the exact mechanism responsible for this phenomenon remains unknown.

In this study, we explore the physical relationship between CIC and ATXN1L and interrogate the mechanism responsible for CIC instability following the loss of ATXN1L. We uncover an ERK-independent mechanism whereby the interaction between CIC and ATXN1L protects CIC from degradation by the E3-ligase TRIM25. Utilizing both in vitro gene expression data from genetically modified cell lines and patient-derived gene expression data from The Cancer Genome Atlas (TCGA), TRIM25 and CIC-ATXN1L were found to antagonistically regulate similar gene sets related to the cell cycle.

**Results**

**Loss of ATXN1L promotes the proteasomal degradation of CIC**

Several studies in human cell lines and mouse studies have reported decreased CIC protein expression following the loss of ATXN1L [17, 25, 26]. In concordance with these studies, decreased CIC protein expression was observed in our ATXN1LKO cell lines [25] which could be partially rescued to levels similar to the untreated parental cell line following treatment with MG132, an inhibitor of the 20S subunit of the proteasome (Fig. 1a), or ectopic expression of a FLAG-tagged ATXN1L construct (Fig. 1b). This decrease in CIC protein expression was found to be exclusive to ATXN1L loss and was not observed following siRNA knockdown of ATXN1, a homolog of ATXN1L (Fig. 1c). Additionally, the introduction of mutant FLAG-tagged ATXN1L-V485A, which is unable to interact with CIC [28] (Additional file 1: Figure S1A), also did not rescue CIC protein expression (Fig. 1d). Density gradient fractionation of ATXN1LWT and ATXN1LKO cell lysates revealed an increase of CIC in higher molecular weight fractions that also contain SUG1, a proteasome subunit (Additional file 1: Figure S1B). Using immunoprecipitation, an increased accumulation of ubiquitin associated with CIC was also observed in ATXN1LKO cells (Fig. 1e, f). Similarly, using proximity ligation assay (PLA), the interaction between CIC and ubiquitin was observed to increase following treatment with MG132 in ATXN1LKO cell lines (Additional file 1: Figure S1C, D) or siRNA knockdown of ATXN1L in ATXN1LWT cells (Fig. 1g, h).

**ATXN1L-mediated CIC instability is independent of ERK activity**

Previous studies have established ERK as a downstream component of the mitogen-activated protein kinase (MAPK) pathway important for regulating the protein expression, localization, and function of CIC through phosphorylation [2, 6–8, 14, 29]. Additionally, transcriptomic analyses of ATXN1LKO cell lines and The Cancer Genome Atlas (TCGA) patient samples have shown upregulation of gene signatures related to MAPK signaling (Fig. 2a) [25]. To further interrogate the mechanism of CIC degradation following ATXN1L loss, we investigated whether ERK activity contributes to the regulation of CIC function in relation to ATXN1L status. Phosphorylated ERK (pThr202/Tyr204) was found to be decreased in our ATXN1LKO cell lines compared to the ATXN1LWT cell lines, detected using ELISA (Fig. 2b) and Western blot (Fig. 2c). Despite the lack of increased ERK activity, ATXN1LKO cell lines displayed mRNA upregulation of the many CIC target genes (ETV1/4/5, DISP6, SPRY4) which are downstream of ERK signaling (Fig. 2d), consistent with previously published data [25]. Further, dual inhibition of MEK and ERK using the small molecule inhibitors trametinib and LY3214996, respectively, did not rescue CIC protein expression in ATXN1LKO cell lines (Fig. 2e) or following siRNA knockdown of ATXN1L in ATXN1LWT cell lines (Fig. 2f).

**Inactivation of CIC by ERK remains intact and independent of ATXN1L**

Despite observing no involvement of ERK in the reduction of CIC protein expression in ATXN1LKO cells, we
Fig. 1 Loss of ATXN1L results in CIC instability. a Representative Western blot of ATXN1L<sup>WT</sup> (HEK) and ATXN1L<sup>KO</sup> cell lines (A10, A30, B21) treated with MG132. DMSO was used as a negative control. Below: barplots showing quantification of CIC protein expression. b Representative Western blot of ATXN1L<sup>WT</sup> (HEK) and ATXN1L<sup>KO</sup> cell lines (A10, A30, B21), ectopically overexpressing FLAG-tagged ATXN1L. Below: barplots showing quantification of CIC protein expression. c Representative Western blot of siRNA knockdown of ATXN1 and ATXN1L in NHA. Scrambled siRNA was used as a negative control. Below: barplots showing quantification of CIC protein expression. d Representative Western blot of ATXN1L<sup>WT</sup> (HEK) and ATXN1L<sup>KO</sup> cell lines (A30) ectopically overexpressing FLAG-tagged wild-type ATXN1L or mutant ATXN1L-V485A. e Barplots showing quantification of ubiquitin Western blots normalized to total CIC Western blots. f Representative Western blot of CIC immunoprecipitation in ATXN1L<sup>WT</sup> (NHA) and ATXN1L<sup>KO</sup> (B82) cell lines treated with MG132. DMSO was used as a negative control. g Immunofluorescence images of proximity ligation assay showing CIC-ubiquitin interaction in ATXN1L<sup>WT</sup> (NHA) cell lines following siRNA knockdown of ATXN1L. Scrambled siRNA was used as a negative control. White bars denote 10 μm. h Tukey boxplots showing quantification of the number of CIC-ubiquitin foci/cell. Western blot quantifications were collected from 3 independent experiments and were normalized to vinculin unless specified otherwise. Error bars represent one standard deviation. PLA quantifications were collected from 65 individual cells. p values were calculated using the two-tailed independent Student’s t test. Statistically significant values are denoted (*p < 0.05, **p < 0.01, ***p < 0.001). Individual data values can be found in Additional file 17: Table S10.
Fig. 2 ATXN1L-mediated CIC instability is independent of ERK activity. 

a Heatmap showing the top 20 upregulated gene sets in ATXN1LKO NHA and HEK cell lines. Terms related to the MAPK pathway are bolded.

b ELISA quantification of phosphorylated ERK (pThr202/Tyr204) in ATXN1LWT and ATXN1LK0 NHA and HEK cell lines. Quantifications were normalized to total ERK.

c Representative Western blot of phosphorylated ERK (pThr202/Tyr204) in ATXN1LWT (NHA) and ATXN1LKO (B82, B16, B21) cell lines. Gene expression was normalized to TBP, and the parental ATXN1LWT (NHA) cell line was used as a relative control.

d Relative mRNA expression of CIC target genes ETV1/4/5, DUSP6, and SPRY4 in ATXN1LWT (NHA) and ATXN1LKO (B82, B16, B21) cell lines.

e Representative Western blot of ATXN1LWT (HEK) and ATXN1LKO (A10, A30, B21) cell lines treated with MEK/ERK inhibitors trametinib/LY3214996. DMSO was used as a negative control. Below: barplot quantifications of CIC expression. Quantifications were normalized to vinculin. Western blot, ELISA, and RT-qPCR quantifications were collected from 3 independent experiments. Error bars represent one standard deviation, \( p \) values were calculated using the two-tailed independent Student's \( t \) test. Statistically significant values are denoted (*\( p < 0.05 \), **\( p < 0.01 \)).
Fig. 3 (See legend on next page.)
were interested to determine if ERK-mediated CIC dysregulation remained intact in our cell system. Treatment of ATXN1L<sup>WT</sup> and ATXN1L<sup>KO</sup> cells with epidermal growth factor (EGF) and fibroblast growth factor (FGF) following serum starvation resulted in an increase of CIC protein expression in both ATXN1L<sup>WT</sup> and ATXN1L<sup>KO</sup> cells (Fig. 3a, Additional file 2: Figure S2A, B), which could be rescued with dual MEK/ERK inhibition (Fig. 3b, Additional file 2: Figure S2C). CIC localization was also not affected by EGF/FGF treatment as observed using immunofluorescence (Fig. 3c). Although CIC protein expression was observed to increase in our cell systems, derepression of several CIC target genes (ETV1/4/5, DUSP6, SPRY4; Fig. 3d, Additional file 2: Figure S2D, E) and decreased CIC binding to the promoter region of target genes (ETV4, DUSP6, SPRY4; Fig. 3e) were observed following EGF/FGF treatment. The increase in CIC protein expression in our cell systems following EGF/FGF treatment was unexpected and thus were further validated in glioblastoma (GBM) cell lines (Additional file 3: Figure S3A, B) and primary brain tumor-initiating cells (BTIC; Additional file 3: Figure S3C).

**CIC degradation is mediated by the E3-ligase TRIM25**

To further investigate CIC interactors which may be responsible for mediating the degradation of CIC protein following ATXN1L loss, CIC immunoprecipitation was performed in ATXN1L<sup>KO</sup> cell lines treated with MG132, and interacting proteins were identified using mass spectrometry. Previously identified CIC interactors such as 14-3-3 regulatory proteins and the ATXN1L homolog ATXN1 were highly enriched (Fig. 4a, Additional file 4: Table S1). Using CIC<sup>KO</sup> cell lines with stably expressing FLAG-tagged CIC-S [30], CIC interaction with 14-3-3 regulatory proteins and the nuclear pore protein TPR was observed to increase following siRNA knockdown of ATXN1L using PLA (Additional file 5: Figure S4A, B, C). CIC was not found to interact with many previously identified proteins involved in transcriptional regulation such as SIN3A, HDAC1/2, and members of the SWI/SNF complex in our ATXN1L<sup>KO</sup> background which may contribute to the dysregulation of CIC target genes [30–32]. Among the most highly enriched CIC interactors was the E3-ligase TRIM25. CIC interaction with TRIM25 was validated using immunoprecipitation (Fig. 4b, Additional file 5: Figure S4D) and TRIM25 was found to be elevated in both ATXN1L<sup>KO</sup> and ATXN1L knockout cell systems. Knockdown of TRIM25 using siRNA was able to induce increased protein expression of both CIC isoforms in ATXN1L<sup>WT</sup> and ATXN1L<sup>KO</sup> cells (Fig. 4d) and decrease mRNA expression of CIC target genes ETV1/4/5 (Fig. 4e). Ectopic overexpression of FLAG-tagged TRIM25 resulted in a further decrease in CIC protein expression in ATXN1L<sup>KO</sup> cells (Fig. 4f). TRIM25 was observed to localize to both the cytoplasm and nucleus (Additional file 5: Figure S4F).

**Validation of CIC-ATXN1L-TRIM25 interactions in additional cell systems**

To further validate our observations, we investigated the relationship between ERK, CIC, ATXN1L, and TRIM25 in additional cellular and biological systems. CIC was found to be expressed in several GBM and primary brain tumor-initiating cell (BTIC) lines (Fig. 5a, b) despite exhibiting increased expression of CIC target genes downstream of MAPK (ETV1/4/5, DUSP6, SPRY4; Additional file 6: Figure S5A, B), compared to NHA cells. Strong expression of CIC was not expected in GBM cell lines as Bunda et al. had previously described ERK-PJA1 mediated degradation of CIC in glioblastoma [14]. Therefore, CIC expression was verified in both low- and high-grade patient glioma samples using immunohistochemistry (n = 17) and found to be expressed across all subtypes, with lower expression in oligodendroglioma (Fig. 5c, d). To determine the role of ERK and ATXN1L in regulating CIC protein expression, GBM and BTIC cell lines were treated with dual MEK and ERK inhibition which did not increase CIC expression, consistent with our previous observations (Fig. 5e, Additional file 7: Figure S6A). Similarly, knockdown of ATXN1L did result in
**Fig. 4** CIC interacts with the E3-ligase TRIM25. 

a. Volcano plot showing CIC-interacting proteins identified using CIC immunoprecipitation followed by mass spectrometry in ATXN1LKO NHA cells. Red data points are high confidence interactors.  

b. Representative Western blot of CIC immunoprecipitation showing interaction with TRIM25 in ATXN1LWT (NHA) and ATXN1LKO (B82) cell lines. Right: barplot showing quantifications of TRIM25 Western blots. Quantifications were normalized to CIC Western blots.  

c. Immunofluorescence images of proximity ligation assay showing FLAG-tagged CIC-S-TRIM25 interaction in ATXN1LWT cells treated with ATXN1L siRNA. Scrambled siRNA was used as a negative control. White bars denote 10 μm. Right: Tukey boxplots showing quantification of the number of FLAG-TRIM25 foci/cell. 

d. Representative Western blot of ATXN1LWT (HEK) and ATXN1LKO (A10, A30, B21) cell lines treated with TRIM25 siRNA. Scrambled siRNA was used as a negative control. Below: barplot quantifications of CIC protein expression. Quantifications were normalized to vinculin.  

e. Relative mRNA expression of CIC and CIC target genes ETV1/4/5 following treatment with TRIM25 siRNA for 48 h. Scrambled siRNA was used as a negative control. Gene expression was normalized to TBP.  

f. Representative Western blot of ATXN1LWT (NHA) and ATXN1LKO (B82) cell lines ectopically overexpressing FLAG-tagged TRIM25. Empty FLAG vector was used as a negative control. Western blot and RT-qPCR quantifications were collected from 3 independent experiments. PLA quantifications were collected from 65 individual cells. Error bars represent one standard deviation. *p values were calculated using the two-tailed independent Student’s t test. Statistically significant values are denoted (*p < 0.05, **p < 0.01, ***p < 0.001). Individual data values can be found in Additional file 17: Table S10.
Fig. 5 (See legend on next page.)
decreased CIC protein expression in both GBM (Additional file 7: Figure S6B) and BTIC (Fig. 5f) cell lines. Derepression of CIC target genes (ETV1/4/5, DUSP6, SPRY4) was also observed following siRNA knockdown of ATXN1L in GBM (Fig. 5g, Additional file 7: Figure S6C) and BTIC (Additional file 7: Figure S6D) cell lines, while siRNA knockdown of TRIM25 resulted in further repression. Dual inhibition of MEK and ERK was not sufficient to rescue decreases in CIC protein expression following siRNA knockdown of ATXN1L (Fig. 5h, Additional file 7: Figure S6E), whereas concurrent knockdown of ATXN1L and TRIM25 was able to rescue decreased CIC protein (Fig. 5i, Additional file 7: Figure S6F).

**TRIM25 amplification and CIC deletion dysregulate similar gene sets**

Probing the TCGA database, alterations in TRIM25 were observed in several cancer types, most notably amplifications in the invasive breast carcinoma (BRCA) and mesothelioma datasets (Fig. 6a). To determine if TRIM25 may regulate the transcription factor functions of CIC, differentially expressed (DE) genes using published gene expression data of TRIM25 knockdown in breast cancer cell lines (BT549 and MDA-MB-231, Additional file 8: Table S2) from Walsh et al. [33] were compared to DE genes identified in CICKO and ATXN1LKO NHA cell lines (Additional file 9: Table S3A, B). As TRIM25 was knocked down, we expected directional discordance between DE genes identified in TRIM25 knockdown versus CICKO/ATXN1LKO. Of the 1531 DE genes identified in the TRIM25 knockdown cell lines (FDR < 0.05, concordant direction), 161 (131 discordant) were shared with CICKO and 122 (104 discordant) were shared with ATXN1LKO DE genes (Fig. 6b, Additional file 10: Table S4A, B). Gene set enrichment analysis of shared discordant genes identified several terms related to cell growth/proliferation and cell attachment/organization which is consistent with CIC/ATXN1L’s function as regulators of the cell cycle and metastasis (Additional file 11: Figure S7, Additional file 12: Table S5A, B). To further validate the relationship between TRIM25 and CIC, differential expression analysis was performed using the TCGA BRCA cohort comparing samples with TRIM25 amplification versus samples with copy number neutral TRIM25. A total of 2789 DE genes were identified (FDR < 0.01, fold change > 1.5; Additional file 13: Table S6A) which were then compared to previously identified DE genes in TCGA type II low-grade glioma (type II LGG, n = 1538), prostate adenocarcinoma (PRAD, n = 842), and stomach adenocarcinoma (STAD, n = 3223) with CIC copy number loss [25], expecting directional concordance. Three hundred forty-seven (321 concordant), 290 (221 concordant), and 682 (553 concordant) DE genes were shared between BRCA and type II LGG, PRAD, and STAD, respectively (Fig. 6c, Additional file 13: Table S6B, C, D). Gene set enrichment analysis of upregulated and directionally concordant DE genes shared between BRCA and type II LGG/PRAD/STAD identified several terms related to cell cycle, consistent with previously published work and our cell line analyses (Fig. 6d, Additional file 14: Table S7). BRCA patients which expressed high TRIM25 expression (top 25%) also showed decreased overall survival (Fig. 6e). In addition to the TCGA BRCA cohort, TRIM25 was further investigated in the TCGA liver hepatocellular carcinoma (LIHC) cohort in which CIC dysregulation, at the proteomic level, has been described as a negative prognostic factor [15, 34]. Similar to the BRCA cohort, LIHC patients with high TRIM25 expression (top 25%) were found to have higher expression of the CIC target genes ETV1/4/5 (Fig. 6f) as well as decreased overall survival (Fig. 6g).

**Discussion**

In this study, we explore the post-translational regulation of CIC in the context of ATXN1L loss and uncover...
Fig. 6 (See legend on next page.)
a novel mechanism of CIC protein regulation independent of ERK activity in several cellular systems and contexts (Fig. 7). The role of ATXN1L as a mediator of CIC repressor function has been well established through several functional studies, both in vitro and in vivo [17, 25, 26]; though little has been explored in regard to the mechanisms of ATXN1L-mediated post-translational stability of CIC. Using isogenic ATXN1LKO cell lines, CIC instability was observed to be a downstream consequence of increased ubiquitin accumulation and that
inhibition of ERK did not affect this CIC instability. Studies investigating the regulation of CIC protein expression in *Drosophila melanogaster* have established ERK as an important mediator of CIC stability through phosphorylation [2, 5–8]. However, unlike mammalian cells, *Drosophila melanogaster* lack an ortholog of ATXN1L suggesting that mammalian cells may have evolved several independent pathways to intricately regulate the post-translational function and stability of CIC. This can be evidenced by the temporal differences in CIC inactivation following the loss of ATXN1L (hours) [25] versus phosphorylation by ERK (minutes) [16], which may suggest that CIC instability resulting from the loss of ATXN1L may be due to an increased rate of normal CIC turnover.

In this study, ERK activity was observed to alleviate CIC’s repressive function, but, contrary to several studies, CIC protein expression increased or remained constant. This discrepancy may be due to context-specific and complex regulatory networks involving CIC in mammalian cells that have not been fully explored. As most mammalian studies investigating the role of ERK in regulating CIC stability have been performed in the context of cancers driven heavily by MAPK activation (melanoma, lung adenocarcinoma, glioblastoma), our observations may be due to post-translational feedback loops that are protective against cytotoxic ERK hyperactivation [35] in cell systems that are not heavily driven by or adapted to high levels of MAPK activation. This study also establishes that the regulation of CIC function and protein stability can be regulated by independent pathways which are dependent on the cellular context.

In addition, this study identified the E3-ligase TRIM25, an important mediator of anti-viral activity [36, 37], as a mediator of CIC post-translational stability. Overexpression of TRIM25 was able to reduce CIC protein expression while siRNA knockdown of TRIM25 was able to stabilize CIC and promote its tumor suppressor function. Utilizing previously published gene expression data and TCGA cohorts, TRIM25 amplification in breast carcinoma was found to dysregulate several shared gene sets, related to cell growth and proliferation, with CIC loss. Interestingly, CIC loss has been linked to increased cancer stem cell-like properties in breast cancer cells [38]. Decreased overall survival was also observed in patients with higher TRIM25 expression in both the BRCA and LIHC TCGA cohorts further supporting the status of CIC function as a prognostic indicator. Although the majority of TRIM25 studies have been focussed on its role as a negative regulator of viral replication, several studies have also suggested that overexpression of TRIM25 may promote tumor progression in hepatocellular carcinoma [39] and lung cancer [40], cell growth and proliferation in prostate adenocarcinoma [41] and breast cancer [42], and metastasis in breast cancer [33], supporting the role of TRIM25 as an oncogene. CIC, which has now been established as a potent tumor suppressor gene, has also been identified as a positive regulator of viral replication [43] which may suggest that the CIC-ATXN1L-TRIM25 axis may be relevant in several different cellular and pathological contexts.

**Conclusions**

Here, we describe TRIM25 as an important mediator of CIC post-translational stability, independent of canonical ERK-mediated stability, in both non-transformed, transformed, and primary mammalian cells. Overexpression of TRIM25 was found to dysregulate similar genes and pathways as CIC loss in both in vitro cell lines and TCGA patient samples suggesting that the CIC-ATXN1L-TRIM25 axis may be an important regulator of cell growth and proliferation in several cancer types including breast carcinoma and liver hepatocellular carcinoma.

**Methods**

**Immunoprecipitation**

For each cell line and replicate, 1–2 15-cm plates at roughly 70–80% confluency were harvested and lysed using Pierce™ IP Lysis Buffer (Thermo Fisher Scientific) supplemented with Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Lysates were incubated on ice for 30 min and homogenized by passing through a 25-gauge needle 15–20 times followed by incubation on ice for 30 min. Insoluble cell debris was pelleted down by centrifugation at 13,000 rpm for 15 min at 4°C. Protein A Dynabeads (Life Technologies) were pre-blocked using 1% BSA, rotating for 1 h at 4°C. One to 2 mg of protein for each replicate was blocked using 30 μL Protein A Dynabeads (Life Technologies). Conjugation of target antibody to Protein A Dynabeads was performed by adding 1–2.5 μg of antibody to the pre-blocked beads in 1 mL of 1% BSA. Blocked lysate was added to the conjugated beads and incubated, rotating for 3 h at 4°C. The beads were washed 3× in IP lysis buffer followed by 2× in PBS then suspended in 2× loading buffer and 1× reducing agent. The beads were boiled at 95°C for 8 min to release captured protein. Antibody information can be found in Additional file 15: Table S8A.

**Cell lysate preparation**

 Harvested cells were lysed using RIPA buffer (Santa Cruz Biotechnology, CA, USA) supplemented with 1× Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Lysates were incubated on ice for 30 min followed by centrifugation at 13,000g for
15 min. Protein concentration was quantified using the BCA protein assay (Thermo Fisher Scientific).

**Western blot sample preparation**

Samples were normalized using PBS if required followed by the addition of 1× loading buffer (Thermo Fisher Scientific) and 1× reducing agent (Thermo Fisher Scientific) then boiled for 10 min at 95 °C.

**Gel electrophoresis and Western blot**

Samples prepared as described above were separated using gel electrophoresis on NuPage 3–8% Tris-Acetate gels run (Life Technologies) in 1× Tris-Acetate running buffer (Life Technologies) or NuPage 10% Bis-Tris gels (Life Technologies) run in 1× MOPS running buffer (Life Technologies). Running buffers were supplemented with oxidizing agent (Life Technologies). Electrophoresis was run at 100 V for 25 min followed by 150 V for 1–2 h. Separated proteins were transferred onto a methanol-activated PVDF membrane (Millipore, Burlington, MA, USA) for 120 min at 100 V in 1× transfer buffer (Life Technologies) with 20% methanol. The membranes were blocked with 5% skim milk in TBS with 0.01% Tween (TBS-T) for 1 h at room temperature followed by overnight incubation with primary antibody. The membranes were incubated with HRP-conjugated secondary antibody (Santa Cruz Biotechnologies) for 1 h at room temperature and washed 3× for 30 min in TBS-T before and after secondary antibody incubation. Protein signal detection was performed using either ECL substrate (Bio-Rad) or SuperSignal West Femto substrate (Thermo Fisher Scientific). Antibody information can be found in Table S1A. Images were captured using an ImageQuant LAS4000 (GE Healthcare Biosciences) or ChemiDoc Imaging System (Bio-Rad), and protein quantifications were performed using the Image J software. Antibody information can be found in Additional file 15: Table S8A.

**Cell culture and ATXN1L knockout generation**

The HEK293a cell line was obtained from Dr. Gregg Morin (Canada’s Michael Smith Genome Sciences Centre, Vancouver, BC, Canada) and authenticated by Genetica DNA Laboratories (Cincinnati, OH, USA). Wild-type IDH1-stable NHA cell line [44] was purchased from Applied Biological Materials (ABM) Inc. (T3022, Richmond, BC, Canada). U251 and U343 glioblastoma cells were obtained from Dr. Shoukat Dedhar (BC Cancer Research Center, Vancouver, BC, Canada), and LN18, LN229, and U87-MG glioblastoma cells were obtained from Dr. Kevin Bennewith (BC Cancer Research Center, Vancouver, BC, Canada). HEK293a, NHA, HOG, U87-MG, U251, and U343 cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Life Technologies) and 5% FBS for LN18 and LN229 cell lines. BTIC cell lines MGG119 [45], BT54, and BT88 [46] were cultured in serum-free Neural Basal Media (Life Technologies) supplemented with N2/B27 (Gibco) and EGF/FGF (20 ng/mL, Peprotech). All cultures were maintained in a 37 °C, 5% CO2 incubator. Cells were tested and verified to be mycoplasma-free using MycoFluor™ Mycoplasma Detection Kit (Invitrogen). Unless otherwise stated, cells were washed once with PBS and harvested via scraping or centrifugation at 70–90% confluency. ATXN1LKO cell lines were generated using the CRISPR/Cas9 genome editing technology as previously described [25].

**Cell culture transfections**

For siRNA knockdown, cells were transfected with Silencer Select (Life Technologies) and Stealth RNAi (Invitrogen) targeted to ATXNL1, ATXN1, or TRIM25. Targeted siRNA information can be found in Additional file 15: Table S8B. Each siRNA was tested independently prior to pooled siRNA experiments (data not shown). Control transfections were performed with Stealth RNAi™ siRNA Negative Control, Med GC (12953500, Thermo Fisher Scientific), or BLOCK-it Fluorescent Oligo (13750062, Invitrogen). FLAG-tagged ATXNL1 (#33242) [47] and FLAG-tagged TRIM25 (#12449) [48] constructs were purchased from Addgene. Transfections were performed at ~70% confluency using TransIT-X2™ Dynamic Delivery System (Mirus Bio LLC) or nucleofection (Mouse Neural Stem Cell Nucleofector Kit: VPG-1004, Lonza, Basel, Switzerland) according to the manufacturer’s protocol. Cells were harvested 24–72 h post-transfection for experiments. Stable transfection of FLAG-tagged CIC-S in CIC-KO cells was performed as previously described [30].

**Drug treatments**

Cell lines were treated overnight for 16 h with 2–10 μM of MG132 prior to harvesting. LY3214996 was used for ERK inhibition at a concentration of 10 nM. Trametinib was used for MEK inhibition at a concentration of 5 nM. Both drugs were dissolved in DMSO. MEK and ERK inhibition were treated overnight for 16 h or the specified time.

**Immunofluorescence and proximity ligation assay**

Cells were seeded and cultured on glass coverslips for 24–72 h and fixed directly to the coverslip using 4% PFA for 20 min at room temperature. Fixed cells were washed in PBS and permeabilized using 0.2% Triton X-100 at room temperature for 20 min. Fixed cells were blocked in 2.5% BSA for 1 h followed by overnight incubation at 4 °C in primary antibody diluted in a blocking solution. Primary antibody information can be found in Additional file 15: Table S8A. Primary treated cells were washed 3× for 5 min with PBS and incubated for 1 h at
room temperature with Alexa Fluor 488- or Alexa Fluor 546-conjugated secondary antibody (Invitrogen), diluted in a blocking solution. For proximity ligation assay (PLA), fixation and permeabilization were performed as above and PLA was performed using Duolink® PLA Technology (Sigma) as per the manufacturer’s protocol. Stained cells were washed in PBS, incubated in DAPI (Invitrogen), and diluted in PBS for 5 min. Phallolidin (Invitrogen) staining was performed as per the manufacturer’s protocol. Stained cells were mounted onto a slide using ProLong™ Gold Antifade Mountant (Invitrogen). Images were captured on Zeiss LSM800 confocal microscope or Colibri Upright LED-based microscope using the ZEN microscope software. PLA signals were quantified using ImageJ.

**Immunohistochemistry**
Slides were deparaffinized using xylene and a decreasing ethanol gradient. Slides were stained using the Ventana BenchMark automated stainer (Roche, Basel, Switzerland). Normal brain and a normal tissue TMA were used as controls. Antibody dilutions can be found in Additional file 15: Table S8A. Stained slides were blindly scored by two independent neuropathologists.

**RT-qPCR**
RNA extraction was performed using the RNeasy Mini Kit (74104, Qiagen) according to the manufacturer’s protocol. One microgram of template RNA was converted to cDNA using the SuperScript™ IV First-Strand Synthesis System (Invitrogen) according to the manufacturer’s protocol. RT-qPCR was performed using 4–12.5 ng of template cDNA using PowerUp™ SYBR™ Green Master Mix (Applied Biosystems) according to the manufacturer’s recommended reaction component amounts and cycling conditions. Primer sequence information can be found in Additional file 15: Table S8C. RT-qPCR reactions were run on a QuantStudio 6 Flex Real-Time PCR System (Thermo Fisher Scientific) using the QuantStudio™ Real-Time PCR software to generate C_T values. Analysis of relative mRNA expression was performed using the 2^(-ΔΔCT) method with TATA-box-binding protein (TBP, IDT Technologies) expression as an endogenous control.

**mRNA sequencing and gene expression analyses**
Sample quality control was performed using the Agilent 2100 Bioanalyzer. Samples were then prepped following the standard protocol for the NEBnext Ultra ii Stranded mRNA (New England Biolabs). Sequencing was performed on the Illumina NextSeq 500 with paired-end 42 bp × 42 bp reads. De-multiplexed read sequences were then aligned to the reference sequence using STAR aligners [49]. Assembly was estimated using Cufflinks ([http://cole-trapnelllab.github.io/cufflinks/](http://cole-trapnelllab.github.io/cufflinks/)) [50] through bioinformatics apps available on the Illumina Sequence Hub. Two independent monoclonal knockouts with 3 biological replicates from different passages were sequenced for each knockout condition. NHA CICKO cell lines were generated as per LeBlanc et al. [19], and NHA ATXN1LK5 cell lines were generated per above from Wong et al. [25]. siTRIM25 RNA sequencing data was obtained from Walsh et al. ([https://doi.org/10.1016/j.celrep.2017.07.052](https://doi.org/10.1016/j.celrep.2017.07.052)) [33], and only genes with FDR < 0.05 and directional concordance in both cell lines (BT549 and MDA-MB-231) were considered differentially expressed and used for downstream analyses. For TCGA analyses, genomic alteration data was generated/downloaded from the cBioPortal for Cancer Genomics ([https://www.cbioportal.org/](https://www.cbioportal.org/)) [51, 52], accessed on 31 October 2019. TCGA Breast Carcinoma (BRCA) [53] and Liver Hepatocellular Carcinoma (LIHC) [54] RNA sequencing data was downloaded from the Broad Genome Data Analysis Center (GDAC) Firehose ([http://firebrowse.org/](http://firebrowse.org/)) [55], accessed on 31 October 2019. Differential expression analysis was performed using DESeq2 [56]. Only BRCA samples with no TRIM25 copy number variations were considered wild-type (n = 449), and BRCA samples with a copy number of 2 or greater were considered amplified (n = 73). BRCA samples used for differential expression analysis can be found in Additional file 16: Table S9.

**Functional enrichment analysis**
The Metascape software ([http://metascape.org](http://metascape.org)) was used to perform functional enrichment analyses using the single and multiple gene lists model [57]. Gene Ontology (GO) biological processes, hallmark gene sets, reactome gene sets, and oncogenic signatures were used for enrichment analyses of all DE genes, with a p value cutoff of 0.05 and a minimum enrichment of 1.5.

**Supplementary information**
Supplementary information accompanies this paper at [https://doi.org/10.1186/s12915-020-00895-0](https://doi.org/10.1186/s12915-020-00895-0).

---

**Additional file 1: Figure S1** Loss of ATXN1L results in CIC instability. A) Representative Western blot of FLAG immunoprecipitation of FLAG-tagged wildtype ATXN1L and mutant ATXN1L-V485A in HEK cells. B) Representative Western blot of cellular fractionation across a sucrose gradient of 20–40% showing localization of CIC. SUG1 was used as a proteasome marker. Quantification of CIC protein/fraction are displayed below. Values were normalized to the cumulative total of CIC in all fractions. C) Immunofluorescence images of proximity ligation assay showing CIC-Ubiquitin interaction in ATXN1LWT (NHA) and ATXN1LKO (B82) cell lines treated with MG132. DMSO was used as negative control. White bars denote 10 μm. D) Tukey boxplots showing quantification of number of CIC-Ubiquitin foci/cell. * PLA quantifications were collected from 65 individual cells; p-values were calculated using the two-tailed independent Student’s t-test. Statistically significant values are denoted (*) = p < 0.05, ** =
Expression was normalized to TBP and scrambled siRNA was used as a negative control. D) Relative mRNA expression of CIC and CIC target genes ETV1/4/5, DUSP6, and SPRY4 in BTIC cell lines MGG119 and BT054 following siRNA knockdown of ATXN1L or TRIM25 for 48 hours. Expression was normalized to TBP and fluorescent RNA was used as a negative control. E) Representative Western blot of GBM cell lines LN18, U251, and U87-MG treated with MEK/ERK inhibitors trametinib/LY3214996 and/or ATXN1L siRNA. DMSO and scrambled siRNA were used as negative controls. Below: barplot quantifications of CIC protein expression. F) Representative Western blot of GBM cell lines LN18, LN229, and U87-MG treated with ATXN1L and/or TRIM25 siRNA. Scrambled siRNA were used as negative control. Below: barplot quantifications of CIC protein expression. * p<0.05 and ** p<0.01. Individual data values can be found in Additional file 17: Table S10.

Additional file 8: Table S2 TRIM25 differentially expressed genes. Differentially expressed genes identified in siTRIM25 vs siCtrl breast carcinoma cell lines. Data from Walsh et al. study [33].

Additional file 9: Table S3 NHA Differential expression analyses. A) Differentially expressed genes: NHA CIC Wildtype vs CIC knockout. B) Differentially expressed genes: NHA ATXN1L wildtype vs ATXN1L knockout.

Additional file 10: Table S4 TRIM25 knockdown vs CIC-ATXN1L knockout. A) Comparison of differentially expressed genes: TRIM25 knockdown vs ATXN1L knockout. B) Comparison of differentially expressed genes: TRIM25 knockdown vs CIC knockout.

Additional file 11: Figure S7 Pathways dysregulated by TRIM25-CIC. Heatmap showing the top 20 enriched gene sets for directionally discordant differentially expressed genes shared between TRIM25 siRNA in BT549 and MDA-MB-231 breast cancer cell lines and CIC/ATXN1L knockout in NHA cell lines. Red terms are upregulated terms related to cell cycle, growth, and proliferation. Blue terms are downregulated terms related to cell structure, organization, and adhesion.

Additional file 12: Table S5 TRIM25-CIC-ATXN1L gene set enrichment analysis. A) Gene set enrichment analysis of upregulated discordant DE genes shared between TRIM25 vs CIC and TRIM25 vs ATXN1L. B) Gene set enrichment analysis of downregulated discordant DE genes shared between TRIM25 vs CIC and TRIM25 vs ATXN1L.

Additional file 13: Table S6 BRCA TRIM25 differential expression analyses. A) Differentially Expressed Genes comparing BRCA samples with TRIM25 amplification and BRCA samples with copy number neutral TRIM25. B) Differentially Expressed Genes shared between BRCA TRIM25 amp and Type II LGG CIC Del. C) Differentially Expressed genes shared between BRCA TRIM25 amp and PRAD CIC Del. D) Differentially Expressed genes shared between BRCA TRIM25 amp and STAD CIC Del.

Additional file 14: Table S7 TCGA Gene set enrichment analyses. Gene set enrichment analysis of differentially expressed genes shared and directionally concordant between BRCA TRIM25 amp and Type II LGG/PRAD/STAD CIC Del.

Additional file 15: Table S8 Antibodies and Primers. A) Antibody information. B) siRNA sequences. C) Primer sequences.

Additional file 16: Table S9 TCGA BRCA Sample. TCGA BRCA Samples used for differential expression analysis (Amplified vs Wildtype).

Additional file 17: Table S10 Data values. Individual data values for figures where n=6.

Abbreviations
ATXN1L: Ataxin-1-like; BRCA: Breast carcinoma; BTIC: Brain tumor-initiating cell; CIC: Capicua; ChIP: Chromatin immunoprecipitation; DE: Differentially expressed; DEA: Differential expression analysis; EGF: Epidermal growth factor; ETS: E26 transformation-specific; FGF: Fibroblast growth factor; GBM: Glioblastoma; GSEA: Gene set enrichment analysis; HMCG: High-mobility group; IP: Immunofluorescence; IP: Immunoprecipitation; LGG: Low-grade glioma; LIHC: Liver hepatocellular carcinoma; MAPK: Mitogen-activated protein kinase; NHA: Normal human astrocyte; ODG: Oligodendroglioma;
Acknowledgements

We thank the members of the Marco Marra laboratory, Gregory Cairncross laboratory, and Jennifer Chan laboratory for their helpful discussions and input. CIC<sup>KO</sup> cell lines were generously provided by the Marco Marra laboratory. Glioblastoma cell lines were generously shared from the Shoukat Dedhateful laboratory and Kevin Bennewith laboratory. BTIC cell lines were generously shared from the Gregory Cairncross laboratory. Lastly, we thank all patients who have contributed to this study.

Authors’ contributions

DW, MAM, and SY designed and oversaw the study. DW, SL, VW, and AL generated the monoclonal knockout cell lines. DW and LS performed the in vitro experiments. DW performed the bioinformatic analyses. ABL and SY verified and scored the IHC. DW wrote and prepared the manuscript. All authors read and approved the final manuscript.

Funding

This work was funded by the BC Cancer Foundation (BCCF) and the Canadian Institutes for Health Research (CIHR).

Availability of data and materials

All data generated or analyzed during this study are included in this published article, its supplementary information files, and publicly available repositories. Supporting data values have also been included in Additional file 17: Table S10. TCGA datasets generated and/or analyzed during the current study are available from https://www.cbioportal.org/ and http://firebrowse.org/. TRIM25 knockdown gene expression data used for analyses are available from Walsh et al. (https://doi.org/10.1016/j.celrep.2017.07.052) [13]. Raw sequencing files are also available in the Gene Expression Omnibus (GEO) repository, accession number: GSE140471 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140471) [58].

Ethics approval and consent to participate

The use of surgical samples was approved by the institutional research ethics board. The use of surgical samples was approved by the institutional research ethics board. The use of surgical samples was approved by the institutional research ethics board.

Consent for publication

Not applicable.

Competing interests

S.Y. has received compensation from Bayer, Hoffmann-La Roche, and Pfizer for participating in advisory boards. All other authors declare that they have no competing interests.

Author details

1Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada. 2Molecular Oncology, BC Cancer Agency, Vancouver, Canada. 3Department of Electrical and Computer Engineering, Technical University of Munich, Munich, Germany. 4Department of Biological and Chemical Engineering, University of British Columbia, Vancouver, Canada. 5Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada. 6Canada’s Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada. 7Vancouver General Hospital, Vancouver, Canada.

Received: 13 December 2019 Accepted: 9 October 2020

References

1. Lee C-J, Chan W-I, Cheung M, Cheng Y-C, Appleby VJ, Orme AT, et al. CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in a developing granule neurons. Mol Brain Res. 2002;106(2–3):151–6.
2. Jin Y, Ha N, Fores M, Xiang J, Glasser C, Malderia J, et al. EGFR/Ras signaling controls Drosophila intestinal stem cell proliferation via Capicua-regulated genes. PLoS Genet. 2015;11(12)e1005634.
3. Yang L, Paul S, Trew KG, Dent LG, Froldi F, Fores M, et al. Minibrain and wings apart control organ growth and tissue patterning through downregulation of Capicua. Proc Natl Acad Sci U S A. 2016;113(38):10583–8.
4. Jimenez G, Shvartsman SY, Parouch 2. The Capicua repressor—a general sensor of RTK signaling in development and disease. J Cell Sci. 2012;125(Pt 6):1383–91.
5. Roch F, Jimenez G, Casanova J. EGFR signalling inhibits Capicua-dependent repression during specification of Drosophila wing veins. Development. 2002;129:992–1002.
6. Jimenez G, Guichet A, Ephrussi A, Casanova J. Relief of gene repression by Torso RTK signaling: role of capicua in Drosophila terminal and dorsoventral patterning. Genes Dev. 2000;14:224–31.
7. Astigarraga S, Grossman R, Diaz-Delfin J, Caetles C, Zev'ev P, Jimenez G. A MAPK docking site is critical for downregulation of Capicua by Torso and EGFR RTK signaling. EMBO J. 2007;26(13):688–77.
8. Tseng AS, Tapon N, Kanda H, Cigizoglu S, Edelmann L, Pollock B, et al. Capicua regulates cell proliferation downstream of the receptor tyrosine kinase/ras signaling pathway. Curr Biol. 2007;17(8):728–33.
9. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Caveness WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20.
10. Yip S, Butterfield YS, Morezova O, Chitarranjan S, Blough MD, An J, et al. Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol. 2012;226(1):7–16.
11. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048):1453–5.
12. Wong D, Yip S. Making heads or tails - the emergence of capicua (CIC) as an important multifunctional tumour suppressor. J Pathol. 2020;250:532–540.
13. Okimoto RA, Wu W, Nanjo S, Olivas S, Lin YK, Ponce RK, et al. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Invest. 2019;129(8):3401–3406.
14. Bunda S, Heir P, Metcalf J, Li ASC, Agnifioti S, Pusch S, et al. CIC protein instability contributes to tumorigenesis in glioblastoma. Nat Commun. 2019;10(1):661.
15. Kim E, Kim D, Lee JS, Yoe J, Park J, Kim CJ, et al. Capicua suppresses hepatocellular carcinoma progression by controlling ETV4-MMP1 axis. Hepatology. 2018;67(6):2287–2301.
16. Okimoto RA, Breitenbucher F, Olivas VR, Wu W, Gini B, Hofree M, et al. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2016;48(1):87–96.
17. Wang B, Kroll EB, Aguiare AJ, Kim M, Widund HR, Doshi MB, et al. ATXN1, CIC, and ETS transcription factors modulate sensitivity to MAPK pathway inhibition. Cell Rep. 2017;18(6):1543–57.
18. Padul V, Epari S, Moyjadi A, Shetty P, Shirsat NV. ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas. Genes Chromosomes Cancer. 2015;54(12):725–33.
19. LeBlanc VG, Firme M, Song J, Chan SY, Lee MH, Yip S, et al. Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade. J Pathol. 2017;242(2):206–220.
20. Gleize V, Atelorn T, Connen de Kerillis L, Labussiere M, Nadaradje AA, Mundwiller E, et al. CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas. Ann Neurol. 2015;78(3):355–74.
21. Kawamura-Saito M, Yamaizaki Y, Kaneko K, Kawaiuchi N, Kanda H, Mukai H, et al. Fusion between CIC and DUX4 up-regulates PEAX3 family genes in Ewing-like sarcomas with t (4,19)(q35;q13) translocation. Hum Mol Genet. 2006;15(13):2125–37.
22. Specht K, Sung YS, Zhang L, Richter GH, Fletcher CD, Antonescu CR. Distinct transcriptional signature and immunoprofile of CIC-DUX4 fusion-positive round cell tumors compared to EWSR1-rearranged Ewing sarcomas: further evidence toward distinct pathologic entities. Genes Chromosomes Cancer. 2014;53(7):622–33.
23. Simon-Carrasco L, Grana O, Salmon M, Jacob HK, Gutierrez A, Jimenez G, et al. Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma. Genes Dev. 2017;31(14):1456–68.
24. Bunda S, Heir P, ASC L, Mamatenj Y, Zadeh G, Aldape K, c-Src phosphorylates and inhibits the function of the CIC tumor suppressor protein. Mol Cancer Res. 2020;18(5):774–786.
25. Wong D, Louskury K, Luan A, Song J, Chan S, LeBlanc V, et al. Transcriptomic analysis of CIC and ATXN1 reveal a functional relationship exploited by cancer. Oncogene. 2018;38:273–290.
26. Lee Y, Fryer JD, Kang H, Crespo-Barreto J, Bowman AB, Gao Y, et al. ATXN1 protein family and CIC regulate extracellular matrix remodeling and lung alveologenesis. Dev Cell. 2011;21(4):746–77.
27. Kim E, Park S, Choi N, Lee J, Yoe J, Kim S, et al. Deficiency of Capicua disrupts bile acid homeostasis. Sci Rep. 2015;5:8272.
28. Kim E, Lu HC, Zoghi HY, Song JJ. Structural basis of protein complex formation and reconfiguration by polyglutamine disease protein Ataxin-1 and Capicua. Genes Dev. 2013;27(8):590–5.
29. Dissanayake K, Toth R, Blakely J, Olsson O, Campbell DG, Prescott AR, et al. ERK (p90RSK)/14-3-3 signalling has an impact on expression of PEAS E3 transcription factors via the transcriptional repressor capicua. Biochem J. 2011;433(3):515–25.
30. Chittaranjan S, Song J, Chan SY, Lee SD, Ahmad ST, Brothers W, et al. Loss of CIC promotes mitotic dysregulation and chromosome segregation defects. 2019.
31. Weissmann S, Closs PA, Siddoli S, Jensen ON, Pollard S, Helin K. The tumor suppressor CIC directly regulates MAPK pathway genes via histone deacetylation. Cancer Res. 2018;78(15):4114–4125.
32. Hwang J, Pan H, Yao J, Elemento O, Zheng H, Paik J. CIC is a critical regulator of neuronal differentiation. JCI Insight. 2020;5(9):e135826.
33. Walsh LA, Alvarez MJ, Sabio EY, Reynold M, Makarov V, Mukherjee S, et al. An integrated systems biology approach identifies TRIM25 as a key determinant of breast cancer metastasis. Cell Rep. 2017;20(7):1623–40. https://www.cell.com/cell-reports/fulltext/S2211-1247(17)31033-82{return_url=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%3Fpii%3FS221112471731033-82%3Fshow=all%3Dtrue#supplementaryMaterial.
34. Hashiba T, Yamashita T, Okada H, Nio K, Hayashi T, Ashina Y, et al. Inactivation of transcriptional repressor Capicua confers sorafenib resistance in human hepatocellular carcinoma. Cell Mol Gastroenterol Hepatol. 2020; 10(2):269-285.
35. Unni AM, Harbourne B, Oh MH, Wild S, Ferrarone JR, Lockwood WW, et al. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. Elife. 2018;7.
36. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I mediated antiviral activity. Nature. 2007;446(7138):916–20.
37. Hage A, Rajbaum R. To TRIM or not to TRIM: the balance of host-virus interactions mediated by the ubiquitin system. J Gen Virol. 2019;100(12):1641–1662.
38. Yoe J, Kim D, Kim S, Lee Y. Capicua restricts cancer stem cell-like properties in breast cancer cells. Oncogene. 2020;39:3489–3506.
39. Zhang Q, Li X, Cui K, Liu C, Wu M, Prochownik EV, et al. The MAP3K13-TRIM25-FBXW7 alpha axis affects c-Myc stability and tumor development. Cell Death Differ. 2019;26:432–443.
40. Qin Y, Cui H, Zhang H. Overexpression of TRIM25 in lung cancer regulates tumor cell progression. Technol Cancer Res Treat. 2016;15(5):707–15.
41. Takayama KI, Suzuki T, Tanaka T, Fujimura T, Takahashi S, Urano T, et al. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with GSK3B in prostate cancer. Oncogene. 2018;37(16):2165–80.
42. Wang Z, Tong D, Han C, Zhao Z, Wang X, Jiang T, et al. Blockade of miR-3614 maturation by IGFBP3 increases TRIM25 expression and promotes breast cancer cell proliferation. ElBioMedicine. 2019;41:357–69.
43. Han J, Perez JT, Chen C, Li Y, Benitez A, Kandasamy M, et al. Genome-wide CRISPR/Cas9 screen identifies host factors essential for influenza virus replication. Cell Rep. 2018;23(2):596–607.
44. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, et al. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res. 2001;61(11):4956–60.
45. Wakiwoto H, Tanaka S, Curry WT, Loebe F, Zhao D, Tateishi K, et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014;20(11):2898–909.
46. Luchman HA, Stiechshin OD, Dang NH, Bough MD, Chenelong C, Kelly JJ, et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncology. 2012;14(2):184–91.
47. Bowman AB, Lam YC, Jafar-Nejad P, Chen HK, Richman R, Samaco RC, et al. Duplication of Atxn1 suppresses SCAT1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nat Genet. 2007;39(3):373–9.
48. Zou W, Zhang DE. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem. 2006;281(7):3989–94.
49. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.
50. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511–5.
51. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(2):404–14.
52. Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
53. Consortium TCGA. Breast invasive carcinoma (TCGA, Fire Hose Legacy). cBioPortal. 2016; https://www.cbioportal.org/study/summary?id=brca_tcga.
54. Consortium TCGA. Liver hepatocellular carcinoma (TCGA, PanCancer Atlas). cBioPortal. 2018; https://www.cbioportal.org/study/summary?id=lihc_tcga_pan_can_atlas_2018.
55. Deng M, Brandelmann J, Kiyokosk Y, Saravia-Agostino N, Perner S. Firebrowse: an R client to the Broad Institute’s Firehose Pipeline. Database (Oxford). 2017;2017:baw160.
56. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(2):550.
57. Zhou Y, Zhou B, Pache L, Chang M, Khoudabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
58. Wong D, Yip S. Transcriptomic analysis of CIC and ATXN1L in normal human astrocytes. Gene Expression Omnibus (GEO). 2020; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140471.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.